Stockscreener 앱 받기
37.46
2.57%
-0.99
시장 영업 전:
37.46
Harrow Inc 주식(HROW)의 최신 뉴스
Harrow Inc (HROW) Institutional Confidence - TradingKey
Harrow Inc (HROW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Harrow Schedules Aug. 11 Call to Discuss Second-Quarter Results - Stock Titan
Harrow Inc (HROW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Harrow, Inc. Revenue Breakdown – NASDAQ:HROW - TradingView
Harrow Inc (HROW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Harrow Inc (HROW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
Harrow Inc (HROW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Harrow Inc (HROW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
HROW|Harrow Inc|Price:39.409|Chg%:+0.959 - TradingKey
Harrow Inc (HROW) Valuation: PE, PB & Fair Value Analysis - TradingKey
HROW|Harrow Inc|Price:41.520|Chg%:-0.360 - TradingKey
BTIG Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $63 - Moomoo
HROW Reiterated by BTIG -- Price Target Maintained at $63.00 - GuruFocus
Harrow, Inc. (HROW) Stock Analysis: Strong Buy Ratings and 52% Potential Upside Drive Investor Interest - DirectorsTalk Interviews
Harrow Inc (HROW) Shares Fall 4.7% -- What GF Score of 80 Tells Investors - GuruFocus
Samsung Bioepis, Harrow present SB11 biosimilar study results By Investing.com - Investing.com South Africa
Harrow (HROW) Unveils Positive Interim Data on SB11 at Retina Sp - GuruFocus
Samsung Bioepis, Harrow present SB11 biosimilar study results - Investing.com India
Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026 - The Manila Times
Samsung Bioepis and Harrow Present Interim Data from a - GlobeNewswire
Harrow presents studies on eye care products at medical meeting By Investing.com - Investing.com Nigeria
Harrow Announces ASRS 2026 Presentation of Studies Supporting IHEEZO and BYOOVIZ in Retina Care - Quiver Quantitative
Harrow presents new clinical data supporting IH... - Pluang
Harrow presents studies on eye care products at medical meeting - Investing.com
Nearly 20,000 Injections: IHEEZO Finds No Evidence of Added Endophthalmitis Risk - Stock Titan
Harrow Health stock trades steady as recent earnings and product expansion frame the outlook - AD HOC NEWS
Harrow Inc (HROW) Shares Surge 3.9% -- What GF Score of 80 Tells Investors - GuruFocus
Harrow Among 3 Prime Growth Stocks With Significant Insider Ownership - simplywall.st
Harrow stock rises on recent results and market value - Ad-hoc-news.de
HROW6348836 Bond Profile — Key Metrics - TradingView
HROW6348836 Bond Coupon Profile — Rate & Payments - TradingView
Harrow Inc (HROW) Shares Surge 3.9% -- What GF Score of 81 Tells Investors - GuruFocus
Harrow: Debt-Fueled Liquidity Masks An Operating Cash Problem (NASDAQ:HROW) - Seeking Alpha
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating, Announces Target Price $59 - Moomoo
Harrow Inc. (HROW) Slips 1% But Holds Key Support Above $40Dividend Growth Stocks - DonanımHaber
Analysts Are Optimistic We'll See A Profit From Harrow, Inc. (NASDAQ:HROW) - 富途牛牛
HROW Q1 2026 Earnings: EPS Misses Estimates Sharply Amid Operational ChallengesQuarterly Earnings - dars.gov.et
HROW News | HARROW INC (NASDAQ:HROW) - ChartMill
Harrow relaunches biosimilar Byooviz in the US - Eyes On Eyecare
Harrow Announces Commercial Launch of BYOOVIZ® in the United States - Sahm
Enterprise value to EBITDA forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Price to book forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Price to earnings forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Price to sales forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Enterprise value to EBIT forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Enterprise value to revenue forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Lake Street Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Harrow Expands Retina Portfolio With US Launch of Byooviz - marketscreener.com
Harrow (HROW) Launches Byooviz, FDA-Approved Biosimilar - GuruFocus
Harrow (HROW) Launches BYOOVIZ Biosimilar in U.S. Market - GuruFocus
A first FDA-approved eye biosimilar returns to U.S. sales - Stock Titan
A Look at Harrow Inc (HROW) After 3.2% Gain -- GF Value $42.31 v - GuruFocus
Cantor Fitzgerald Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $88 - Moomoo
Harrow, Inc. Actuals & Estimates (NASDAQ:HROW) - TradingView
HROW Forecast — Price Target — Prediction for 2027 - TradingView
How Grow Funds’ Exit and Weaker Earnings Recast Harrow’s (HROW) Growth Narrative and Governance Choices - simplywall.st
GROW Small Cap Equity Fund Exits Its Position in Harrow (HROW) During First QuarterPost-Earnings Reaction - DonanımHaber
GROW Small Cap Equity Fund Covered Its Position in Harrow (HROW) in Q1 - Insider Monkey
Harrow Inc. (HROW) Edges Higher, Consolidating Above Key $40 Support LevelETF Premium Discount - dars.gov.et
Form 4 Harrow Health Inc For: 22 June By Investing.com - Investing.com Australia
0.30%
2.01%
자본화:
|
볼륨(24시간):